-- In a first-phase study of multiple sclerosis , Serono Genetics Institute
identified 80 candidate genes utilizing the Affymetrix Mapping 100K SNP
Arrays.03)

Shares used in computing basic
net income (loss) per share 62,351 59,903
Shares used in computing diluted
net income (loss) per share 69,081 59,903

" Dr.,
Sangamo's vice president of therapeutics and Chief Medical Officer.

commemorate selfish

Affymetrix Reports First Quarter 2005 Results

, compared to total
revenue of $78.6 million
was related to the sale of products to Perlegen. A
live webcast of the conference call can be accessed by visiting the Investor
Relations section of the Company's website at http: //www.,
Authors Commentary on Sangamo's Zinc Finger DNA-Binding Protein Approach

RICHMOND , Calif.D.

fingerprints sequenced

First quarter product sales included GeneChip(R) array revenue of
$47.
-- The GeneChip System(R) 3000Dx, the first microarray-based in vitro
diagnostics platform, was commercially launched in the United States.
For the second quarter of 2005 the Company expects product and product
related revenue of approximately $83 million, total revenue of around
$87 million, and net income per diluted share of $0.D. High is a Howard Hughes Medical Institute
Investigator, an attending physician in the Hematology Division of The
Children's Hospital of Philadelphia and the current President of the American
Society of Gene Therapy (ASGT). The ZFN(TM) technology that we have developed
provides a potential solution to specifically and permanently correcting a
mistake in a cellular gene without the need for integration of foreign DNA
into the genome.
The most advanced ZFP Therapeutic(TM) development programs are currently in
Phase I clinical trials for evaluation of safety in patients with peripheral
artery disease and diabetic neuropathy.

genomics eukaryotic

2 million was
related to the sale of products to Perlegen Sciences, Inc.
Total operating costs and expenses were $69 . Affymetrix' patented
photolithographic manufacturing process provides the most information capacity
available today on an array, enabling researchers to use a whole-genome
approach to analyze the relationship between genetics and health.
The June 2 issue of Nature also features a review of Sangamo's work
written by Katherine A., who characterized the work as "a
considerable step towards a successful genetic-engineering approach to
treating human disease.
In Sangamo's study, highly specific engineered ZFNs designed to bind to
sequences close to an X-linked SCID-causing mutation in the IL2R-gamma gene
resulted in a high percentage of the cells undergoing gene correction.

organelles mutation

PT on
April 28, 2005 at the following numbers: domestic: 888-286-8010,
international: 617-801-6888; passcode for both: 77047580.


AFFYMETRIX, INC.


AFFYMETRIX, INC.26 $(0. High, M. Until now this goal has remained out of
reach for human therapeutics. High comments that Sangamo's ZFN(TM) strategy for
site-specific gene correction combines two biological processes that are
highly evolutionarily conserved: 1) the targeting of a functional domain to a
specific DNA sequence using a ZFP, in this case the functional domain is an
enzyme that causes a break in the DNA strand, and 2) the repair of that break
by a natural process known as homologous recombination." The authors show rates of gene correction by homologous
recombination in cultured cells that are 15,000 to 20,000 times higher when a
break is introduced by ZFNs than when no break is introduced.

biomolecules organelles

Total revenue for the quarter was $88 .
Selling, general and administrative expenses were $29.m. Affymetrix technology is used by the world's top
pharmaceutical, diagnostic and biotechnology companies as well as leading
academic , government and not-for-profit research institutes. In
addition, it was observed that approximately one third of the corrected cells
acquired the desired modification on both chromosomes.

This press release may contain forward-looking statements based on
Sangamo's current expectations .

phenotypes commemorate

Royalties and other revenue were $1.8 million for the first
quarter of 2005 compared to $70.12 to approximately $1.m. While further
work will be required to optimize the system for therapeutic use, the gene
correction efficiencies established here may be sufficient to achieve a
therapeutic effect.

About Zinc Finger DNA Binding Proteins
Zinc Finger DNA-binding Proteins (ZFPs ) are a naturally occurring class of
DNA binding proteins.

phenotypes snp

Company Reports 26% Growth in Array Revenue and Reiterates Full-Year Revenue
Targets

SANTA CLARA , Calif.8 million in the first quarter of 2004. Affymetrix
is headquartered in Santa Clara, Calif . The company maintains important sales
and marketing operations in Europe and Asia and has about 900 employees
worldwide. The research
data, previously released in an advanced online publication , demonstrate the
use of the Company's zinc finger DNA-binding protein (ZFP) technology to
achieve highly efficient, permanent correction of a disease-causing gene in
primary human cells. Louis.

biosciences accumulated

The
Company reported net income of $16.6 million, of which $2. Since then,
Affymetrix GeneChip (R) technology has become the industry standard in
molecular biology research.

All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding Affymetrix '
"expectations," "beliefs," "hopes," "intentions," "strategies," or the like.
Affymetrix expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward -looking statements contained
herein to reflect any change in Affymetrix' expectations with regard thereto
or any change in events, conditions, or circumstances on which any such
statements are based. President of the American Society of Gene Therapy, Katherine High, M.
High stated that more work will be necessary before the technique can
successfully be translated into humans but points out that if the rates of
correction that have been achieved by the authors in T-cells can be
recapitulated in CD34-expressing hematopoietic stem cells, "then they will
probably be adequate to restore immune function."
"I would once again like to acknowledge and congratulate my colleagues at
Sangamo on this ground-breaking work," said Edward Lanphier, Sangamo's
president and CEO.

About Sangamo
Sangamo BioSciences, Inc.

biomolecules selfish

Product and product related revenue increased to $84 .9 million. In addition,
investors and other interested parties can listen by dialing domestic:
800 -884-5695, international: 617-786-2960., and Bedford, Mass. (Nasdaq: SGMO) today announced that Company research published in an
article in the June 2 print issue of Nature magazine represents a significant
advance in the ability to specifically and efficiently modify the human genome
and provides the scientific foundation for potential therapeutic approaches
for a variety of genetic disorders and infectious diseases.com. These forward-looking statements include,
without limitation, references to the research and development of novel ZFP
TFs and ZFNs, clinical trials and therapeutic applications of Sangamo's ZFP
technology platform.

noncoding prokaryotic

3 million in the first quarter of 2004.
-- To investigate the genetic origins of atherosclerosis, Harvard
University Medical School-Partners Healthcare for Genetics and Genomics have
adopted the GeneChip Mapping 500K Arrays for their studies.

Affymetrix' management team will host a conference call on April 21st at
2:00 p. Comparably high
levels of correction were observed in primary human T-cells. This permits the
delivery of a variety of functional domains to a gene-specific location. Other therapeutic development programs
are focused on ischemic heart disease, congestive heart failure, cancer,
neuropathic pain, and infectious and monogenic diseases. Sangamo assumes no obligation to update
the forward-looking information contained in this press release.

glossaries genomics

Research and development expenses were $17.3 million in the first quarter of 2004.
-- Affymetrix launched the GeneChip(R) Mapping 500K Array Early Access
program for genome-wide association studies.

Financial Outlook
For fiscal year 2005, the Company reiterates its guidance of product and
product related revenue of approximately $390 million and raises guidance for
net income per diluted share from $1.

About Affymetrix
Affymetrix scientists invented the world's first high-density microarray
in 1989 and began selling the first commercial microarray in 1994. "As Dr. However, the ultimate aim is to correct a mutation
and thus enable the production of a normal protein under the control of the
cell's intrinsic regulatory signals . Sangamo's core
competencies enable the engineering of a class of DNA-binding proteins known
as zinc finger DNA-binding proteins (ZFPs).

prokaryotic selfish

Researchers scanned 10 chromosomes at high resolution using next-generation,
pre-commercial Affymetrix technology.com. These and other risk factors are discussed in Affymetrix'
Form 10-K for the year ended December 31, 2004 and other SEC reports,
including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. As she goes on to
explain, "the most remarkable feature of this complex process is the frequency
at which it occurs. "We look forward to presenting these findings and data
from related ZFNTM programs in sickle cell anemia, Wiskott-Aldrich Syndrome
and HIV/AIDS this week at the Annual ASGT meeting being held in St.expressinglife .

transgenics organelles

6 million in the same period in 2004.8 million in the first
quarter of 2005 compared to $23.16. An archived
webcast of the conference call will be available under the Investor Relations
section of the Company's website at http://www.03)
Diluted net income (loss) per share $0. For gene modification,
ZFPs are being used in combination with a DNA cutting enzyme (endonuclease)
functional domain to generate ZFNs that facilitate the correction of mutant
gene sequences that cause disease or the disruption of genes that facilitate
disease progression.

biosciences genotypes

8 million or
$0.

Quarterly Highlights

-- The National Cancer Institute and Affymetrix published new insights
into the structure and function of the human genome in the journal Science ."

Study Results
Mutations in the gene encoding the IL2R-gamma protein invariably cause
X-linked SCID or so-called Bubble-boy disease. In the case of therapeutic gene regulation,
ZFPs are being engineered to either turn on therapeutically beneficial genes
or turn off the expression of disease-causing genes.

phenotypes snp

9 million, and instrument revenue of
$15.6 million in the same period of 2004. Product
and product related gross margin was 74.4 percent in the first quarter of 2004. The passcode for both is
25840962.

eukaryotic phenotypes

Affymetrix shipped approximately 50 GeneChip Systems in the
quarter , increasing the cumulative systems shipped to more than 1,225.4 million in the first quarter of 2004 .16.
Such statements, including Affymetrix' financial outlook for 2005, are subject
to risks and uncertainties that could cause actual results to differ
materially for Affymetrix from those projected , including, but not limited to,
risks of the Company's ability to achieve and sustain higher levels of
revenue, higher gross margins, reduced operating expenses, market acceptance,
personnel retention , global economic conditions, the fluctuations in overall
capital spending in the academic and biotechnology sectors, changes in
government funding policies, unpredictable fluctuations in quarterly revenues ,
uncertainties related to cost and pricing of Affymetrix products, dependence
on collaborative partners, uncertainties relating to sole source suppliers,
uncertainties relating to FDA, and other regulatory approvals, risks relating
to intellectual property of others and the uncertainties of patent protection
and litigation.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)
(UNAUDITED)

March 31, December 31,
2005 2004
(Note 1)
ASSETS
Current assets:
Cash and cash equivalents $62,950 $42,595
Available-for-sale securities 191,480 163,120
Accounts receivable 68,908 89,441
Accounts receivable from Perlegen Sciences 4,624 3,964
Inventories 19,849 17,997
Prepaid expenses and other current assets 5,854 5,833
Total current assets 353,665 322,950
Property and equipment, net 65,414 64,179
Acquired technology rights, net 62,905 64,334
Goodwill 18,601 18,601

Notes receivable from employees 1,935 1,900
Other assets 28,759 27,807
$531,279 $499,771


LIABILITIES AND STOCKHOLDERS ' EQUITY
Current liabilities:
Accounts payable and accrued liabilities $49,646 $62,963
Deferred revenue - current portion 37,292 33,776
Total current liabilities 86,938 96,739
Deferred revenue - long-term portion 25,942 29,463
Other long-term liabilities 4,310 4,382
Convertible notes 120,000 120,000
Stockholders ' equity:
Common stock 630 616
Additional paid-in capital 434,893 407,258
Deferred stock compensation (4,265) (4,265)
Accumulated other comprehensive loss (2,336) (3,371)
Accumulated deficit (134,833) (151,051)

Total stockholders' equity 294,089 249,187

$531,279 $499,771


Note 1: The condensed consolidated balance sheet at December 31, 2004 has
been derived from the audited consolidated financial statements
at that date included in the Company's Form 10-K for the fiscal
year ended December 31, 2004.

cloning genomics

03 per diluted share in the first quarter of 2004.9 million for the
first quarter of 2005, compared to $74.
Cost of product and product related revenue was $21.1 million during the first
quarter of 2005 compared to $17.6 million for the
first quarter of 2005 compared to $28. In an expanded follow-up study, they will use Affymetrix Mapping 500K
Arrays .affymetrix.affymetrix. The DNA recognition and binding function of ZFPs can be
engineered and thus directed to a targeted sequence of DNA. is focused on the research and development of
novel DNA-binding proteins for therapeutic gene regulation and modification. Actual results may differ materially from these
forward-looking statements due to a number of factors, including technological
challenges , Sangamo's ability to develop commercially viable products and
technological developments by our competitors.

chromosome geneticists

A replay of the conference call will be available until 5:00 p. Referring to
Sangamo 's data on correction of a mutation responsible for X-linked SCID, Dr. Patients with such mutations do
not produce a functional IL2R-gamma protein; never develop a functional immune
system and die of severe infections within 12-18 months of birth. The expected downstream
changes in both RNA and protein levels were also observed.

biosciences genomics

,
(Nasdaq: AFFX) today reported its results for the first quarter of 2005.2 million, or $0.6 million in the first quarter of 2004, of which $1. Since
its introduction in 2004, Affymetrix has shipped over 60 GeneChip 3000Dx
systems to its diagnostic partners and clinical laboratories.
-- bioMerieux, a Powered by Affymetrix(TM) partner, will develop and
market in vitro diagnostics for breast cancer on the Affymetrix platform. PT to review its operating results for the first quarter of 2005 and
to provide financial guidance for the second quarter and full-year 2005.com., with manufacturing facilities in
Sacramento, Calif.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)

Three Months Ended
March 31,
2005 2004
Revenue:
Product sales $73,551 $61,091
Product related revenue 11,317 13,522
Total product and product related revenue 84,868 74,613
Royalties and other revenue 1,560 2,371
Revenue from Perlegen Sciences 2,187 1,649
Total revenue 88,615 78,633
Costs and expenses:
Cost of product sales 19,279 20,732
Cost of product related revenue 2,505 2,856
Cost of revenue from Perlegen Sciences 1,242 1,371
Research and development 17,090 17,296
Selling, general and administrative 29,597 28,269
Stock-based compensation 83 324
Total costs and expenses 69,796 70,848
Income from operations 18,819 7,785
Interest income and other, net 714 1,075
Interest expense (427) (9,834)

Income (loss) before income taxes 19,106 (974)
Income tax provision (2,888) (859)
Net income (loss) $16,218 $(1,833)

Basic net income (loss) per share $0.
"The recognition and overwhelmingly positive response to this work by the
scientific and medical community is gratifying," said Dale Ando, M. For more information about Sangamo, visit the company's
web site at http://www.

prokaryotic microarray

24 per diluted share in
the first quarter of 2005, as compared to a net loss of $1.6 million for the first quarter of
2005 compared to $2.3 percent in the first quarter of 2005
compared to 68.

cloning mutation

-- In a major initiative to study cancer and develop new diagnostic tests,
Institut Curie and Affymetrix launched a translational medicine program.

Sangamo BioSciences' Gene Correction Technology Published in Nature Magazine Is Seen as 'Considerable Step Towards a Successful Genetic-Engineering Approach

In this study, Sangamo scientists demonstrated the use of engineered zinc
finger nucleases (ZFNTM) to correct errors in the DNA sequence of the
IL2R-gamma gene that causes X-linked severe combined immunodeficiency disease
(X-linked SCID) . Correction was achieved in a high percentage of treated
cells without the need for selection.D . See the company's SEC filings,
and in particular, the risk factors described in the company's Annual Report
on Form 10-K and its most recent 10-Q.

phenotypes genetics

NOTE: Affymetrix, the Affymetrix logo, Powered by Affymetrix, and
GeneChip are trademarks owned or used by Affymetrix, Inc.24 $(0."
In her review, Dr.

The study of genes

glossaries genomics

, Affymetrix, Inc.
-- To accelerate the translation of basic research into clinical practice,
Affymetrix and the Karolinska Institutet initiated a strategic alliance which
will initially include genetic analyses and measurement of gene expression in
patients with atherosclerosis, breast cancer, rheumatoid arthritis, asthma and
dyslexia., Sangamo BioSciences ,
Inc. Importantly, gene correction was
site-specific, permanent and eliminated the need for integration of any
foreign DNA sequence, a cause of problems in certain gene therapy studies.
High pointed out in her News and Views article, most gene therapies are
gene-addition therapies. ZFPs
are being developed for two significant therapeutic applications: gene
regulation and gene modification. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs)
for therapeutic gene modification as a treatment and possible cure for a
variety of monogenic diseases, such as sickle cell anemia, and for infectious
diseases such as HIV.

phenotypes transgenics

7 million, reagent revenue of $9. More than 1,200
systems have been shipped around the world and nearly 3,000 peer-reviewed
papers have been published using the technology.
Our goal is to move these programs efficiently through preclinical testing and
to work with our clinical collaborators to advance this technology into the
clinic to benefit patients . By engineering ZFPs that recognize
a specific DNA sequence Sangamo has created ZFP transcription factors
(ZFP TF(TM)) that can control gene expression and, consequently, cell
function.

biomolecules geneticists

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)